



GlaxoSmithKline Consumer
Healthcare Pakistan
Limited
Sandoz Nagar, Petaro
Road, Jamshoro,
Sindh, 76100,
Pakistan

UAN +92 21 111 475 725
www.pk-consumerhealthcare.gsk.com

23 August 2022

Deputy General Manager
Pakistan Stock Exchange Limited
Stock Exchange Building,
Stock Exchange Road,
Karachi.

SUBJECT: Disclosure of Material Information – BoD Approval of Change of Company’s Name

Dear Sir / Madam,

This is with reference to section 96 and 131 of the Securities Act, 2015 and Clause 5.6.1(a) of PSX Limited Regulations. The Company hereby conveys the following material information:

The Board, in its meeting held on 23 August 2022, passed the following resolution:

RESOLVED THAT the name of the Company be changed from “**GlaxoSmithKline Consumer Healthcare Pakistan Limited**” to “**Haleon Pakistan Limited**” subject to relevant regulatory and shareholder approvals, with effect from the date of the Certificate of Incorporation on Change of Name issued by the Securities and Exchange Commission of Pakistan.

FURTHER RESOLVED THAT the name **Haleon Pakistan Limited** shall be accompanied by the phrase “*Formerly known as GlaxoSmithKline Consumer Healthcare Pakistan Limited*” in parenthesis as prescribed under section 13 of the Companies Act, 2017.

FURTHER RESOLVED THAT upon the change of the name being approved by the Registrar of Companies, the Board of Directors authorizes the calling of an Extraordinary General Meeting to alter the Memorandum and Articles of Association of the Company to reflect the change of the name “**GlaxoSmithKline Consumer Healthcare Pakistan Limited**” to the name “**Haleon Pakistan Limited**” wheresoever appearing in the said Memorandum and Articles of Association.

FURTHER RESOLVED THAT the Chief Executive Officer, and / or the Chief Financial Officer and / or the Company Secretary of the Company be and are hereby authorized to jointly and / or severally do all such acts, deeds and things as may be deemed necessary or ancillary to give effect to the foregoing resolution including without limitation to take actions and execute documents as may be necessary for the purpose of changing the name of the Company and to alter the Memorandum and Articles of Association, including, but not limited to, filing the requisite applications before the Securities and Exchange Commission of Pakistan and to sign all statutory returns, forms, notices, circulars and documents as may be required in connection with these resolutions.

Due to the demerger of the consumer healthcare business from the GSK Group, Haleon plc was formed as an independent listed company and listed on the London Stock Exchange on 18 July 2022. It commenced trading on the New York Stock Exchange on 20 July 2022. Further information regarding the aforementioned is available at <https://www.haleon.com/investors/demerger-information>. The reason for the change of the name of the Company to Haleon Pakistan Limited, which is a part of the Haleon Group, is to reflect the said change in Pakistan. This shall have no effect on the principal line of business of the Company.

Disclosure form in terms of Section 96 and 131 of the Securities Act, 2015 is also attached.

You may please inform the TRE Certificate holders of the Exchange accordingly.

For and on behalf of
GlaxoSmithKline Consumer Healthcare Pakistan Limited



Ms. Mashal Mohammad
Company Secretary

Cc: Executive Director / HOD,
Offsite-II Department, Supervision Division,
Securities and Exchange Commission of Pakistan,
NIC Building, 63 Jinnah Avenue,
Blue Area, Islamabad.

**SCHEDULE
DISCLOSURE FORM**

Name of Company:	GlaxoSmithKline Consumer Healthcare Pakistan Limited		
Registered Office:	Sandoz Nagar, Petaro Road, Jamshoro Sindh, 76100.		
Date of Report:	23 August 2022		
Contact Information:	Mashal Mohammad Company Secretary		
Telephone No.:			+92-111-475-725
Fax No.:			N/A
Email Address:	rawail.x.adeel@haleon.com		

Disclosure of inside information by listed company in terms of Section 96 and 131 of the Securities Act, 2015.

RESOLVED THAT the name of the Company be changed from “**GlaxoSmithKline Consumer Healthcare Pakistan Limited**” to “**Haleon Pakistan Limited**” subject to relevant regulatory and shareholder approvals, with effect from the date of the Certificate of Incorporation on Change of Name issued by the Securities and Exchange Commission of Pakistan.

FURTHER RESOLVED THAT the name **Haleon Pakistan Limited** shall be accompanied by the phrase “*Formerly known as GlaxoSmithKline Consumer Healthcare Pakistan Limited*” in parenthesis as prescribed under section 13 of the Companies Act, 2017.

FURTHER RESOLVED THAT upon the change of the name being approved by the Registrar of Companies, the Board of Directors authorizes the calling of an Extraordinary General Meeting to alter the Memorandum and Articles of Association of the Company to reflect the change of the name “**GlaxoSmithKline Consumer Healthcare Pakistan Limited**” to the name “**Haleon Pakistan Limited**” wheresoever appearing in the said Memorandum and Articles of Association.

FURTHER RESOLVED THAT the Chief Executive Officer, and / or the Chief Financial Officer and / or the Company Secretary of the Company be and are hereby authorized to jointly and / or severally do all such acts, deeds and things as may be deemed necessary or ancillary to give effect to the foregoing resolution including without limitation to take actions and execute documents as may be necessary for the purpose of changing the name of the Company and to alter the Memorandum and Articles of Association, including, but not limited to, filing the requisite applications before the Securities and Exchange Commission of Pakistan and to sign all statutory returns, forms, notices, circulars and documents as may be required in connection with these resolutions.

Due to the demerger of the consumer healthcare business from the GSK Group, Haleon plc was formed as an independent listed company and listed on the London Stock Exchange on 18 July 2022. It commenced trading on the New York Stock Exchange on 20 July 2022. Further information regarding the aforementioned is available at <https://www.haleon.com/investors/demerger-information>. The reason for the change of the name of the Company to Haleon Pakistan Limited, which is a part of the Haleon Group, is to reflect the said change in Pakistan. This shall have no effect on the principal line of business of the Company.

For and on behalf of
GlaxoSmithKline Consumer Healthcare Pakistan Limited



Ms. Mashal Mohammad
Company Secretary